Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
11:12pm, Thursday, 31'st Oct 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief E
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
06:20pm, Thursday, 31'st Oct 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.22 per share a year ago.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
04:30pm, Thursday, 17'th Oct 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30,
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
04:00pm, Thursday, 03'rd Oct 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
10:55am, Tuesday, 06'th Aug 2024
The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
09:15am, Tuesday, 06'th Aug 2024
24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
10:10pm, Thursday, 01'st Aug 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Exe
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
06:51pm, Thursday, 01'st Aug 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.45 per share a year ago.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The positive preli
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
04:05pm, Thursday, 18'th Jul 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Comp
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
04:47pm, Wednesday, 17'th Jul 2024
VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delt
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
10:01am, Thursday, 04'th Jul 2024
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regard
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and gr
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
02:31pm, Thursday, 06'th Jun 2024
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #hepatitisd--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatiti
